RadNet, Inc. (RDNT)
USD 53.38
(2.24%)
USD 53.38
(2.24%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 98.69 Million USD | 100.59% |
| 2022 | 46.36 Million USD | -43.84% |
| 2021 | 82.55 Million USD | 55.08% |
| 2020 | 53.23 Million USD | -23.82% |
| 2019 | 69.87 Million USD | 126.24% |
| 2018 | 30.88 Million USD | -38.29% |
| 2017 | 50.05 Million USD | 30.07% |
| 2016 | 38.48 Million USD | -1.63% |
| 2015 | 39.11 Million USD | -26.62% |
| 2014 | 53.3 Million USD | 22.25% |
| 2013 | 43.6 Million USD | -3.59% |
| 2012 | 45.22 Million USD | -10.72% |
| 2011 | 50.66 Million USD | 31.81% |
| 2010 | 38.43 Million USD | -1.09% |
| 2009 | 38.85 Million USD | 19.23% |
| 2008 | 32.59 Million USD | 53.97% |
| 2007 | 21.16 Million USD | 30.09% |
| 2006 | 16.27 Million USD | 17.6% |
| 2005 | 13.83 Million USD | 41.52% |
| 2004 | 9.77 Million USD | -20.93% |
| 2003 | 12.36 Million USD | 9.25% |
| 2002 | 11.31 Million USD | -40.76% |
| 2001 | 19.1 Million USD | 30.87% |
| 2000 | 14.59 Million USD | 508.17% |
| 1999 | 2.4 Million USD | 114.54% |
| 1998 | -16.5 Million USD | -115.28% |
| 1997 | -7.66 Million USD | -318.32% |
| 1996 | -1.83 Million USD | 96.53% |
| 1995 | -52.77 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 11.75 Million USD | -62.22% |
| 2024 Q2 | 35.51 Million USD | 196.56% |
| 2023 FY | 93 Million USD | 100.59% |
| 2023 Q1 | 6.67 Million USD | -69.12% |
| 2023 Q3 | 43.25 Million USD | 76.96% |
| 2023 Q4 | 31.1 Million USD | -28.08% |
| 2023 Q2 | 24.44 Million USD | 266.38% |
| 2022 Q2 | 19.55 Million USD | 896.84% |
| 2022 Q4 | 21.6 Million USD | 211.97% |
| 2022 Q3 | 6.92 Million USD | -64.6% |
| 2022 FY | 46.36 Million USD | -43.84% |
| 2022 Q1 | 1.96 Million USD | -57.82% |
| 2021 Q4 | 4.65 Million USD | -85.72% |
| 2021 Q1 | 17.65 Million USD | -15.55% |
| 2021 Q2 | 27.67 Million USD | 56.79% |
| 2021 FY | 82.55 Million USD | 55.08% |
| 2021 Q3 | 32.57 Million USD | 17.67% |
| 2020 Q4 | 20.9 Million USD | -10.58% |
| 2020 Q3 | 23.37 Million USD | 12958.66% |
| 2020 Q2 | 179 Thousand USD | 102.04% |
| 2020 FY | 53.23 Million USD | -23.82% |
| 2020 Q1 | -8.77 Million USD | -137.71% |
| 2019 Q3 | 16.85 Million USD | -23.35% |
| 2019 Q2 | 21.98 Million USD | 202.39% |
| 2019 Q1 | 7.27 Million USD | 1436.4% |
| 2019 FY | 69.87 Million USD | 126.24% |
| 2019 Q4 | 23.27 Million USD | 38.1% |
| 2018 Q4 | -544 Thousand USD | -103.31% |
| 2018 FY | 30.88 Million USD | -38.29% |
| 2018 Q1 | -888 Thousand USD | -104.85% |
| 2018 Q2 | 15.87 Million USD | 1887.16% |
| 2018 Q3 | 16.44 Million USD | 3.64% |
| 2017 Q2 | 14.16 Million USD | 109.89% |
| 2017 Q4 | 18.3 Million USD | 68.83% |
| 2017 Q3 | 10.83 Million USD | -23.46% |
| 2017 Q1 | 6.74 Million USD | -54.92% |
| 2017 FY | 50.05 Million USD | 30.07% |
| 2016 FY | 38.48 Million USD | -1.63% |
| 2016 Q1 | 2.98 Million USD | -71.45% |
| 2016 Q2 | 8.07 Million USD | 170.8% |
| 2016 Q3 | 12.45 Million USD | 54.13% |
| 2016 Q4 | 14.96 Million USD | 20.22% |
| 2015 FY | 39.11 Million USD | -26.62% |
| 2015 Q2 | 13.38 Million USD | 787.77% |
| 2015 Q3 | 17.22 Million USD | 28.73% |
| 2015 Q4 | 10.45 Million USD | -39.35% |
| 2015 Q1 | -1.94 Million USD | -113.08% |
| 2014 Q2 | 15.64 Million USD | 107.29% |
| 2014 Q1 | 7.54 Million USD | -44.92% |
| 2014 FY | 53.3 Million USD | 22.25% |
| 2014 Q4 | 14.87 Million USD | -2.36% |
| 2014 Q3 | 15.23 Million USD | -2.63% |
| 2013 Q1 | 8.32 Million USD | 24.78% |
| 2013 FY | 43.6 Million USD | -3.59% |
| 2013 Q4 | 13.7 Million USD | 59.55% |
| 2013 Q2 | 12.98 Million USD | 55.98% |
| 2013 Q3 | 8.58 Million USD | -33.85% |
| 2012 Q4 | 6.67 Million USD | -51.79% |
| 2012 Q1 | 11.25 Million USD | -35.65% |
| 2012 Q2 | 13.46 Million USD | 19.68% |
| 2012 Q3 | 13.84 Million USD | 2.78% |
| 2012 FY | 45.22 Million USD | -10.72% |
| 2011 Q2 | 14.82 Million USD | 81.65% |
| 2011 FY | 50.66 Million USD | 31.81% |
| 2011 Q4 | 17.48 Million USD | 71.49% |
| 2011 Q3 | 10.19 Million USD | -31.21% |
| 2011 Q1 | 8.15 Million USD | -36.18% |
| 2010 FY | 38.43 Million USD | -1.09% |
| 2010 Q3 | 11.38 Million USD | 14.8% |
| 2010 Q1 | 4.35 Million USD | -59.27% |
| 2010 Q2 | 9.91 Million USD | 127.9% |
| 2010 Q4 | 12.78 Million USD | 12.3% |
| 2009 Q2 | 9.23 Million USD | -5.79% |
| 2009 FY | 38.85 Million USD | 19.23% |
| 2009 Q1 | 9.79 Million USD | 38.74% |
| 2009 Q4 | 10.68 Million USD | 16.84% |
| 2009 Q3 | 9.14 Million USD | -0.96% |
| 2008 Q2 | 8.43 Million USD | 25.2% |
| 2008 FY | 32.59 Million USD | 53.97% |
| 2008 Q3 | 10.35 Million USD | 22.76% |
| 2008 Q4 | 7.06 Million USD | -31.79% |
| 2008 Q1 | 6.73 Million USD | 300.51% |
| 2007 Q2 | 10.33 Million USD | 82.13% |
| 2007 FY | 21.16 Million USD | 30.09% |
| 2007 Q1 | 5.67 Million USD | 0.0% |
| 2007 Q3 | 8.88 Million USD | -14.07% |
| 2007 Q4 | -3.36 Million USD | -137.84% |
| 2006 FY | 16.27 Million USD | 17.6% |
| 2006 Q2 | 3.93 Million USD | -17.45% |
| 2006 Q1 | 4.76 Million USD | 21.23% |
| 2006 Q3 | 3.63 Million USD | -7.7% |
| 2005 Q2 | 4.19 Million USD | 34.11% |
| 2005 Q4 | 3.93 Million USD | -13.39% |
| 2005 Q1 | 3.13 Million USD | 55.54% |
| 2005 FY | 13.83 Million USD | 41.52% |
| 2005 Q3 | 4.54 Million USD | 8.14% |
| 2004 Q2 | 1.08 Million USD | -53.0% |
| 2004 FY | 9.77 Million USD | -20.93% |
| 2004 Q4 | 2.01 Million USD | -24.21% |
| 2004 Q1 | 2.29 Million USD | -22.39% |
| 2004 Q3 | 2.65 Million USD | 145.93% |
| 2003 Q2 | 3.55 Million USD | -43.41% |
| 2003 Q3 | -143 Thousand USD | -104.03% |
| 2003 Q4 | 2.96 Million USD | 2170.63% |
| 2003 Q1 | 6.27 Million USD | 134.48% |
| 2003 FY | 12.36 Million USD | 9.25% |
| 2002 Q3 | 2.43 Million USD | 1414.05% |
| 2002 Q4 | 2.67 Million USD | 10.12% |
| 2002 FY | 11.31 Million USD | -40.76% |
| 2002 Q1 | 4.73 Million USD | 9.13% |
| 2002 Q2 | -185 Thousand USD | -103.91% |
| 2001 Q2 | 5.34 Million USD | 7.24% |
| 2001 Q4 | 4.33 Million USD | -4.97% |
| 2001 Q3 | 4.56 Million USD | -14.58% |
| 2001 Q1 | 4.98 Million USD | 18.27% |
| 2001 FY | 19.1 Million USD | 30.87% |
| 2000 Q2 | 4.23 Million USD | 18.33% |
| 2000 Q1 | 3.57 Million USD | 37.61% |
| 2000 FY | 14.59 Million USD | 508.17% |
| 2000 Q4 | 4.21 Million USD | 1.14% |
| 2000 Q3 | 4.16 Million USD | -1.62% |
| 1999 Q1 | -1.4 Million USD | -16.67% |
| 1999 Q3 | 1 Million USD | -9.09% |
| 1999 FY | 2.4 Million USD | 114.54% |
| 1999 Q2 | 1.1 Million USD | 178.57% |
| 1999 Q4 | 2.6 Million USD | 160.0% |
| 1998 Q3 | -16.5 Million USD | -4225.0% |
| 1998 Q2 | 400 Thousand USD | 100.0% |
| 1998 Q4 | -1.2 Million USD | 92.73% |
| 1998 FY | -16.5 Million USD | -115.28% |
| 1998 Q1 | 200 Thousand USD | 140.0% |
| 1997 Q2 | -400 Thousand USD | -100.0% |
| 1997 Q3 | -1.9 Million USD | -375.0% |
| 1997 Q4 | -500 Thousand USD | 73.68% |
| 1997 FY | -7.66 Million USD | -318.32% |
| 1997 Q1 | -200 Thousand USD | 96.15% |
| 1996 FY | -1.83 Million USD | 96.53% |
| 1996 Q3 | -4 Million USD | -3900.0% |
| 1996 Q2 | -100 Thousand USD | -107.69% |
| 1996 Q1 | 1.3 Million USD | 0.0% |
| 1996 Q4 | -5.2 Million USD | -30.0% |
| 1995 FY | -52.77 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 201.376% |
| Biodesix, Inc. | -41.34 Million USD | 338.733% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | 1337.855% |
| Castle Biosciences, Inc. | -67.97 Million USD | 245.192% |
| DarioHealth Corp. | -56.18 Million USD | 275.652% |
| Exact Sciences Corporation | -215.01 Million USD | 145.903% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 91.004% |
| Illumina, Inc. | -1.06 Billion USD | 109.233% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | 1059.791% |
| iSpecimen Inc. | -11.16 Million USD | 983.641% |
| Standard BioTools Inc. | -76.6 Million USD | 228.847% |
| 23andMe Holding Co. | -321.35 Million USD | 130.713% |
| Medpace Holdings, Inc. | 336.82 Million USD | 70.698% |
| NeoGenomics, Inc. | -107.73 Million USD | 191.61% |
| Inotiv, Inc. | -81.46 Million USD | 221.16% |
| Psychemedics Corporation | -2.92 Million USD | 3478.877% |
| Prenetics Global Limited | -52.51 Million USD | 287.946% |
| Precipio, Inc. | -7.62 Million USD | 1395.236% |
| Sotera Health Company | 276.69 Million USD | 64.33% |
| Star Equity Holdings, Inc. | -4.34 Million USD | 2370.985% |
| Exagen Inc. | -22.83 Million USD | 532.18% |
| Natera, Inc. | -446.24 Million USD | 122.117% |
| Aspira Women's Health Inc. | -18.85 Million USD | 623.536% |
| Neogen Corporation | 58.66 Million USD | -68.244% |
| Myriad Genetics, Inc. | -123.7 Million USD | 179.787% |
| ICON Public Limited Company | 956.15 Million USD | 89.678% |
| Bionano Genomics, Inc. | -215.24 Million USD | 145.853% |
| CareDx, Inc | -101.9 Million USD | 196.857% |
| Check-Cap Ltd. | -19.28 Million USD | 611.728% |
| Twist Bioscience Corporation | -220.83 Million USD | 144.693% |
| Guardant Health, Inc. | -564.72 Million USD | 117.477% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | 3905.423% |
| Fulgent Genetics, Inc. | -72.69 Million USD | 235.769% |
| Sera Prognostics, Inc. | -39.82 Million USD | 347.852% |
| OPKO Health, Inc. | -157.02 Million USD | 162.856% |
| Personalis, Inc. | -109.93 Million USD | 189.777% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | 1001.072% |
| Star Equity Holdings, Inc. | -4.34 Million USD | 2370.985% |
| MDxHealth SA | -27.32 Million USD | 461.17% |
| Prenetics Global Limited | -52.51 Million USD | 287.946% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | 1038.119% |
| Mainz Biomed B.V. | -26.64 Million USD | 470.419% |
| Trinity Biotech plc | -27.04 Million USD | 464.936% |
| Neuronetics, Inc. | -30.55 Million USD | 423.025% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | 1337.855% |